Guardant Health saw the highest growth of 274% in patent filings in October and 199% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 274% and grants by 74%. GlobalData’s DataBook provides a comprehensive analysis of Guardant Health‘s patent filings and grants. Buy the databook here.
Guardant Health has been focused on protecting inventions in United States(US) with 17 publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 46% filings and 55% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Guardant Health is filings its patents. Among the top granted patent authorities, Guardant Health has 55% of its grants in United States(US) and 45% in European Patent Office(EPO).
Patents related to genomics and healthtech lead Guardant Health's portfolio
See Also:
Guardant Health has the highest number of patents in genomics followed by, healthtech and rare diseases. For genomics, nearly 42% of patents were filed and 50% of patents were granted in Q4 2023.
Healthcare it related patents lead Guardant Health portfolio followed by breast cancer, and colorectal tumor
Guardant Health has highest number of patents in healthcare it followed by breast cancer, colorectal tumor, liver cancer, and lung cancer. For healthcare it, nearly 13% of patents were filed and 12% of patents were granted in Q4 2023.
For comprehensive analysis of Guardant Health's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.